CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1201 Informed consent Wiki 1.00
drug1984 Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D015817 Eye Infections NIH 1.00
D003231 Conjunctivitis NIH 0.71
D007249 Inflammation NIH 0.20
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000509 Conjunctivitis HPO 0.71

There is one clinical trial.

Clinical Trials


1 Immediate and Mid-term Implications of the Covid-19 Pandemic on the Physical, Behavioural and Mental Health of Healthcare Workers: A Cohort Study of Doctor, Nurses and Other Health Care Workers

The current COVID-19 pandemic has affected more than 3 million people worldwide across more than 200 countries. In the United Kingdom alone, at the end of April, there were almost 160,000 confirmed cases with more than 20,000 deaths. This has undoubtedly had significant physical and economical impact on the public. Healthcare workers are at high risk of developing life-threatening infectious diseases with increased exposure to patients' blood and bodily fluids. As such, health care workers arguably experience heightened anxiety and are predisposed to greater negative psycho-social impact from the current COVID-19 pandemic. The aim of this study is to evaluate the physical and psychological impact of COVID-19 on healthcare workers. This will be performed in two phases. In phase 1, investigators will collect information to evaluate the current psychiatric symptom profile (in particular, screening for anxiety or depression related symptoms), alcohol use, sleep-related complaints and overall well-being among healthcare workers who participate in this survey (with a focus on junior doctors). In addition the association of these mental health and behavioural parameters with the prevalence of stressful occasions, such as long-hours, unpredictability of work / redeployment, availability of personal protection equipment and concerns regarding family/relationship and self will be assessed. In phase 2, investigators will then reassess for the development or progression of psychiatric symptoms, use of alcohol and other substances, behavioural or interpersonal relationship changes as well as physical well-being at 6 weeks and 4- months. Physical well-being is assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. Specifically, investigators will study the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for well-being of family members, on work morale and anxiety levels. Another aim is also study the longer term mental health consequences of the current pandemic on health care workers.

NCT04433260 Mental Health Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index Other: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. Other: Informed consent

Primary Outcomes

Description: Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety.

Measure: Presence of anxiety at baseline

Time: baseline

Description: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression

Measure: Presence of depression at baseline

Time: baseline

Description: Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Higher score corresponding to more severe degree of anxiety.

Measure: Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.

Time: baseline

Description: Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression

Measure: Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study

Time: 4 months

Description: Self reported, assessed based on the questions regarding the presence of symptoms with presence of either self reported positive test, or self-isolation of 7 or more days.

Measure: Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study

Time: 4 months

Secondary Outcomes

Description: Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety.

Measure: Change in prevalence of anxiety from baseline

Time: 4 months

Description: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression

Measure: Change in prevalence of depression from baseline

Time: 4 months followup

Description: This is based on questions derived from the Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

Measure: Prevalence of sleep-related issues at baseline

Time: At baseline

Description: Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

Measure: Change in prevalence of sleep-related issues from baseline

Time: 4-month follow-up

Description: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

Measure: Prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline.

Time: baseline

Description: This is based on questions derived from the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS). Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety.

Measure: Proportion of those with low mental wellbeing at baseline

Time: baseline

Description: Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS). Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety

Measure: Change in proportion of those with low mental wellbeing from baseline to the end of study.

Time: 4-month follow-up

Description: Self-reported measures through responses to direct questions relevant to work-related practices in the survey

Measure: Prevalence of those who report concern related to work-place practices.

Time: At baseline

Description: Self-reported measures through responses to direct questions relevant to work-related practices in the survey

Measure: Change in the prevalence from baseline of those who report concern related to work-place practices.

Time: 6-week

Description: Self-reported measures through responses to direct questions relevant to work-related practices in the survey

Measure: Change in the prevalence from baseline of those who report concern related to work-place practices.

Time: 4 months

Description: Self-reported measures through responses to survey questions

Measure: Change in behavioural habits, such as smoking and alcohol intake from baseline to the end of study

Time: 4-month follow-up

Description: Self reported, based on the presence of symptoms with either self reported positive test, or self-isolation of 7 or more days.

Measure: Proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19

Time: Baseline


No related HPO nodes (Using clinical trials)